Horizon Technology Finance Provides $35 Million Venture Loan Facility to Onkos Surgical庐 to Accelerate Commercialization of Novel Antibacterial Implant Technology
Horizon Technology Finance (NASDAQ: HRZN) has provided a $35 million venture loan facility to Onkos Surgical, with $30 million initially funded. The funding will accelerate manufacturing and commercialization of 狈补苍辞颁别辫迟鈩�, an FDA-granted antibacterial coating technology for orthopedic implants.
NanoCept received the first-ever FDA De Novo authorization for an antibacterial coating technology on orthopedic implants in April 2024. The technology has demonstrated up to 99.999% kill rate in standardized in-vitro testing of common operating room bacteria. Onkos Surgical, backed by investors including 1315 Capital, Canaan Partners, and SV Health Investors, operates in a $3 billion market developing solutions for adult and pediatric patients with bone loss from tumor, trauma, or failed orthopedic implant revision.
Horizon Technology Finance (NASDAQ: HRZN) ha fornito una linea di prestiti per venture capital di 35 milioni di dollari a Onkos Surgical, con 30 milioni inizialmente finanziati. Il finanziamento accelera la produzione e la commercializzazione di 狈补苍辞颁别辫迟鈩�, una tecnologia di rivestimento antibatterico approvata dalla FDA per impianti ortopedici.
NanoCept ha ricevuto la prima autorizzazione De Novo della FDA per una tecnologia di rivestimento antibatterico su impianti ortopedici nell'aprile 2024. La tecnologia ha dimostrato un tasso di uccisione fino al 99,999% in test in vitro standardizzati su batteri comuni delle sale operatorie. Onkos Surgical, sostenuta da investitori tra cui 1315 Capital, Canaan Partners e SV Health Investors, opera in un mercato da 3 miliardi di dollari sviluppando soluzioni per pazienti adulti e pediatrici con perdita ossea dovuta a tumori, traumi o revisioni di impianti ortopedici fallite.
Horizon Technology Finance (NASDAQ: HRZN) ha proporcionado una l铆nea de pr茅stamo de capital de riesgo de 35 millones de d贸lares a Onkos Surgical, con 30 millones inicialmente financiados. La financiaci贸n acelerar谩 la fabricaci贸n y comercializaci贸n de 狈补苍辞颁别辫迟鈩�, una tecnolog铆a de recubrimiento antibacteriano aprobada por la FDA para implantes ortop茅dicos.
NanoCept recibi贸 la primera autorizaci贸n De Novo de la FDA para una tecnolog铆a de recubrimiento antibacteriano en implantes ortop茅dicos en abril de 2024. La tecnolog铆a ha demostrado una tasa de eliminaci贸n de hasta el 99,999% en pruebas in vitro estandarizadas de bacterias comunes en quir贸fanos. Onkos Surgical, respaldada por inversionistas que incluyen 1315 Capital, Canaan Partners y SV Health Investors, opera en un mercado de 3 mil millones de d贸lares desarrollando soluciones para pacientes adultos y pedi谩tricos con p茅rdida 贸sea debido a tumores, traumas o revisiones fallidas de implantes ortop茅dicos.
Horizon Technology Finance (NASDAQ: HRZN)電� Onkos Surgical鞐� 3,500毵� 雼煬鞚� 氩れ矘 雽�於� 鞁滌劋鞚� 鞝滉车頄堨溂氅�, 3,000毵� 雼煬臧� 觳橃潓鞐� 鞛愱笀鞚� 歆�鞗愲皼鞎橃姷雼堧嫟. 鞚� 鞛愱笀鞚� 狈补苍辞颁别辫迟鈩�鞚� 鞝滌“ 氚� 靸侅毄頇旊ゼ 臧�靻嶍檾頃� 瓴冹瀰雼堧嫟. NanoCept電� FDA搿滊秬韯� 鞀轨澑氚涭潃 鞝曧槙鞕戈臣 鞛勴攲霝�韸鸽ゼ 鞙勴暅 頃窢 旖旐寘 旮办垹鞛呺媹雼�.
NanoCept電� 2024雲� 4鞗� 鞝曧槙鞕戈臣 鞛勴攲霝�韸胳棎 雽�頃� 頃窢 旖旐寘 旮办垹搿� FDA鞚� 斓滌磮 De Novo 鞀轨澑鞚� 氚涭晿鞀惦媹雼�. 鞚� 旮办垹鞚� 鞚茧皹 靾橃垹鞁� 靹戈窢鞐� 雽�頃� 響滌頇旊悳 鞚� 牍勴姼搿� 韰岇姢韸胳棎靹� 斓滊寑 99.999%鞚� 靷搓窢鞙潉 鞛呾頄堨姷雼堧嫟. 1315 Capital, Canaan Partners, SV Health Investors 霌膘潣 韴瀽鞛愲摛 歆�鞗愳潉 氚涬姅 Onkos Surgical鞚� 膦呾枒, 鞕胳儊, 霕愲姅 鞁ろ尐頃� 鞝曧槙鞕戈臣 鞛勴攲霝�韸� 靾橃垹鞚� 瓴瓣臣搿� 爰� 靻愳嫟鞚� 臧�歆� 靹膘澑瓿� 靻岇晞 頇橃瀽霌れ潉 鞙勴暅 靻旊（靺橃潉 臧滊皽頃橂姅 30鞏� 雼煬 攴滊鞚� 鞁滌灔鞐愳劀 頇滊彊頃橁碃 鞛堨姷雼堧嫟.
Horizon Technology Finance (NASDAQ: HRZN) a fourni une ligne de cr茅dit de 35 millions de dollars 脿 Onkos Surgical, dont 30 millions ont 茅t茅 financ茅s initialement. Ce financement va acc茅l茅rer la fabrication et la commercialisation de 狈补苍辞颁别辫迟鈩�, une technologie de rev锚tement antibact茅rien approuv茅e par la FDA pour les implants orthop茅diques.
NanoCept a re莽u la premi猫re autorisation De Novo de la FDA pour une technologie de rev锚tement antibact茅rien sur des implants orthop茅diques en avril 2024. La technologie a d茅montr茅 un taux d鈥櫭﹍imination allant jusqu'脿 99,999% lors de tests in vitro standardis茅s sur des bact茅ries courantes en salle d鈥檕p茅ration. Onkos Surgical, soutenue par des investisseurs tels que 1315 Capital, Canaan Partners et SV Health Investors, op猫re sur un march茅 de 3 milliards de dollars, d茅veloppant des solutions pour les patients adultes et p茅diatriques souffrant de perte osseuse due 脿 des tumeurs, des traumatismes ou des r茅visions d'implants orthop茅diques 茅chou茅es.
Horizon Technology Finance (NASDAQ: HRZN) hat eine Venture-Darlehensfazilit盲t in H枚he von 35 Millionen US-Dollar an Onkos Surgical bereitgestellt, wobei zun盲chst 30 Millionen US-Dollar finanziert wurden. Die Finanzierung wird die Herstellung und Kommerzialisierung von 狈补苍辞颁别辫迟鈩�, einer von der FDA genehmigten antibakteriellen Beschichtungstechnologie f眉r orthop盲dische Implantate, beschleunigen.
NanoCept erhielt im April 2024 die erste FDA De Novo Genehmigung f眉r eine antibakterielle Beschichtungstechnologie an orthop盲dischen Implantaten. Die Technologie hat eine Sterberate von bis zu 99,999% in standardisierten In-vitro-Tests mit h盲ufigen Operationssaal-Bakterien nachgewiesen. Onkos Surgical, unterst眉tzt von Investoren wie 1315 Capital, Canaan Partners und SV Health Investors, ist in einem Markt von 3 Milliarden Dollar t盲tig, der L枚sungen f眉r erwachsene und p盲diatrische Patienten mit Knochenschwund aufgrund von Tumoren, Traumata oder fehlgeschlagenen orthop盲dischen Implantatrevisionen entwickelt.
- Secured $35 million venture loan facility with $30 million initially funded
- First-ever FDA De Novo authorization for antibacterial coating technology (April 2024)
- Technology demonstrates 99.999% bacteria kill rate in testing
- Operating in a substantial $3 billion market
- None.
Insights
Onkos intends to use the proceeds of the loan facility to accelerate manufacturing and commercialization of 狈补苍辞颁别辫迟鈩�, a groundbreaking, antibacterial coating technology that is used on FDA-granted orthopaedic implants to reduce bacterial contamination at the time of implantation. Bacterial contamination of implants is a significant clinical challenge that can have devastating implications for patients and poses a substantial financial burden to the healthcare system.
鈥淥nkos Surgical is disrupting the orthopaedic marketplace with a suite of differentiated products, including NanoCept,鈥� said Gerald A. Michaud, President of Horizon. 鈥淲e are pleased to support the growth of Onkos as it continues to innovate novel solutions that address diverse unmet needs in a growing and important market segment.鈥�
Onkos Surgical is a leading innovator in the musculoskeletal space, developing technologies to address the clinical challenges associated with complex orthopaedic procedures. The company鈥檚 portfolio of products provides solutions for adult and pediatric patients who have bone loss from tumor, trauma, or revision of failed orthopaedic implants. In , NanoCept was granted the first-ever FDA De Novo authorization for an antibacterial coating technology used on orthopaedic implants, demonstrating Onkos鈥檚 innovation capabilities. NanoCept has demonstrated excellent safety and biocompatibility, with broad-spectrum efficacy (up to
鈥淲e are committed to transforming the standard of care across complex orthopaedic procedures, with the goals of providing benefit to patients, clinicians, and health systems while creating value for our investors as we expand our footprint in a
About Horizon Technology Finance
Horizon Technology Finance Corporation (NASDAQ: HRZN), externally managed by Horizon Technology Finance Management LLC, an affiliate of Monroe Capital, is a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries. The investment objective of Horizon is to maximize its investment portfolio鈥檚 return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. Horizon is headquartered in
About Onkos Surgical
Onkos Surgical is a leader in innovative solutions for complex orthopaedic conditions. With our novel product portfolio, surgeons are better informed about patient-specific clinical challenges and can plan and implement more precise reconstructions. Our personalized approach supports improved patient outcomes and experiences using the latest innovations in antibacterial implant coatings, virtual surgical planning, 3D anatomic modeling and printing, implant design, and workflow optimization. More than 350 of the leading academic medical institutions in the US choose Onkos for their complex revision and tumor orthopaedic cases. For more information on Onkos Surgical and its products and services, please visit .
Forward-Looking Statements
Statements included herein may constitute 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company鈥檚 filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.
View source version on businesswire.com:
Investor Relations:
ICR
Garrett Edson
ir@horizontechfinance.com
(646) 200-8885
Media Relations:
ICR
Chris Gillick
HorizonPR@icrinc.com
(646) 677-1819
Source: Horizon Technology Finance Corporation
FAQ
What is the size of Horizon Technology Finance's (HRZN) loan facility to Onkos Surgical?
When did Onkos Surgical receive FDA De Novo authorization for NanoCept?
What is the bacterial kill rate of Onkos Surgical's NanoCept technology?
What is the market size for Onkos Surgical's products?
Who are the major investors backing Onkos Surgical?
